News

InBio and Beckman Coulter Partner to Advance Food Allergy Diagnostics

InBio, a global leader in high-quality, purified allergen proteins, and Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, are collaborating to enhance the performance of basophil activation tests (BAT) for food allergy research. The collaboration integrates InBio’s Food Protein Standards and purified allergens with the Next-Generation Basophil Activation Test (BAT) platform from Beckman Coulter Life Sciences.

InBio’s Food Protein Standards and purified allergen components are potent, biologically active proteins derived from foods such as peanut, egg, milk, tree nuts, and shellfish. These reagents are a critical component for BAT tests, and are validated for immunological consistency, ensuring reproducibility in high-sensitivity assays.

The Next-Generation BAT* by Beckman Coulter Life Sciences is a research use only breakthrough in functional allergy testing that offers researchers a powerful tool to assess allergic sensitization and reactivity with greater precision. Leveraging advanced flow cytometry and automation to measure basophil activation in response to allergen exposure, the Next-Generation BAT is an in vitro alternative to oral food challenges. The integration of InBio’s food proteins ensures consistency in allergen stimulation, reducing variability and improving test interpretation.

The Next-Generation BAT powered by InBio allergens can test for multiple allergens at once through a blood draw — saving hours of food testing and exposure to potentially harmful reactions.

Read more here.

Recent News

10/27/2025

Virginia can lead biotech manufacturing renaissance – if policymakers help

Last week, pharmaceutical giant Merck broke ground on a new $3 billion facility in Virginia that will create 8,000 construction jobs and 500 permanent manufacturing jobs. The new 400,000 square-foot, state-of-the-art plant isn’t merely the latest addition to Virginia’s rapidly growing biotech industry footprint. It’s a sign that America is making quick progress towards President

10/22/2025

Virginia Catalyst Announces Round 19 of Grant Funding

The Virginia Catalyst announced today that it is accepting letters of intent (LOI) for Grant Round 19 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “We at the Virginia Catalyst are pleased to provide funding in support of the Governor’s

10/21/2025

SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers

SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been awarded up to $34 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop technology as part of the POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) program. This pioneering program